GlobeNewswire PharmaOriginal article
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3LasofoxifenePositive
AI Analysis
Summary
LeonaBio reported that its Phase 3 ELAINE-3 trial of lasofoxifene for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer is on track to complete enrollment in Q4 2026 with topline data expected in the second half of 2027.
Clinical Trial Data
Phase
Phase 3
Importance:5/10
Sentiment:
0.30
Phase 3 trialenrollment updatebreast cancertopline data expected
Read the original article
Published by GlobeNewswire Pharma on August 14, 2026 8:05 PM